학술논문

Randomized, double-blind trial comparing indinavir alone, zidovudine alone and indinavir plus zidovudine in antiretroviral therapy-naive hiv-infected individuals with CD4 cell counts between 50 and 250/mm3
Document Type
article
Source
Revista do Instituto de Medicina Tropical de São Paulo, Vol 42, Iss 1, Pp 27-36 (2000)
Subject
Randomized study
Double blind clinical trial
HIV
AIDS
Protease inhibitors
Indinavir
Zidovudine
Disease progression
Therapy
Clinical endpoint
Arctic medicine. Tropical medicine
RC955-962
Infectious and parasitic diseases
RC109-216
Language
English
ISSN
1678-9946
Abstract
Treatment with indinavir has been shown to result in marked decreases in viral load and increases in CD4 cell counts in HIV-infected individuals. A randomized double-blind study to evaluate the efficacy of indinavir alone (800 mg q8h), zidovidine alone (200 mg q8h) or the combination was performed to evaluate progression to AIDS. 996 antiretroviral therapy-naive patients with CD4 cell counts of 50-250/mm3 were allocated to treatment. During the trial the protocol was amended to add lamivudine to the zidovudine-containing arms. The primary endpoint was time to development of an AIDS-defining illness or death. The study was terminated after a protocol-defined interim analysis demonstrated highly significant reductions in progression to a clinical event in the indinavir-containing arms, compared to the zidovudine arm (p